(Q39783358)

14 September 2017

title

Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection (English)

1 reference

14 September 2017

George Sellhorn

1

1 reference

14 September 2017

Zachary Caldwell

series ordinal

2

1 reference

14 September 2017

Christine Mineart

series ordinal

3

1 reference

14 September 2017

Leonidas Stamatatos

series ordinal

4

1 reference

14 September 2017

language of work or name

English

0 references

publication date

24 October 2009

1 reference

14 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

430-436

1 reference

14 September 2017

cites work

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Prospects of HIV Env modification as an approach to HIV vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

High-level expression and purification of a designed angiopoietin-1 chimeric protein, COMP-Ang1, produced in Chinese hamster ovary cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Transient transfection factors for high-level recombinant protein production in suspension cultured mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Production of recombinant protein therapeutics in cultivated mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Effects of pCIneo and pCEP4 expression vectors on transient and stable protein production in human and simian cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

SEAP expression in transiently transfected mammalian cells grown in serum-free suspension culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Enhancement of transient gene expression by fed-batch culture of HEK 293 EBNA1 cells in suspension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Orbital shaker technology for the cultivation of mammalian cells in suspension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Large-scale transfection of mammalian cells for the fast production of recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

High-density transient gene expression in suspension-adapted 293 EBNA1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Transient expression and purification of chimeric heavy chain antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Production of chimeric heavy-chain antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.028

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.10.028

1 reference

14 September 2017

1 reference